Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O95389
UPID:
CCN6_HUMAN
Alternative names:
CCN family member 6; WNT1-inducible-signaling pathway protein 3
Alternative UPACC:
O95389; Q3KR29; Q5H8W4; Q6UXH6
Background:
Cellular communication network factor 6, also known as CCN family member 6 or WNT1-inducible-signaling pathway protein 3, plays a crucial role in mitochondrial electron transport and respiration. Its regulation of mitochondrial function is essential for postnatal skeletal growth and cartilage homeostasis, as evidenced by research findings (PubMed:27252383, PubMed:10471507).
Therapeutic significance:
The protein is implicated in Progressive pseudorheumatoid dysplasia, a disorder marked by joint stiffness, swelling, motor weakness, and contractures. This disease highlights the protein's vital role in cartilage and bone integrity, suggesting that targeting CCN family member 6 could offer new avenues for therapeutic intervention.